These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24059236)

  • 1. Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease.
    Caramori G; Di Stefano A; Casolari P; Kirkham PA; Padovani A; Chung KF; Papi A; Adcock IM
    Curr Med Chem; 2013; 20(35):4317-49. PubMed ID: 24059236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Atypical Chemokines and Chemokine Receptors Pathways in the Pathogenesis of COPD.
    Nucera F; Lo Bello F; Shen SS; Ruggeri P; Coppolino I; Di Stefano A; Stellato C; Casolaro V; Hansbro PM; Adcock IM; Caramori G
    Curr Med Chem; 2021; 28(13):2577-2653. PubMed ID: 32819230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease.
    Donnelly LE; Barnes PJ
    Trends Pharmacol Sci; 2006 Oct; 27(10):546-53. PubMed ID: 16911834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CC-chemokine receptors in chronic obstructive pulmonary disease.
    Bracke KR; Demedts IK; Joos GF; Brusselle GG
    Inflamm Allergy Drug Targets; 2007 Jun; 6(2):75-9. PubMed ID: 17692030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antiinflammatory therapies for COPD.
    Gross NJ
    Chest; 2012 Nov; 142(5):1300-1307. PubMed ID: 23131938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemokine receptors in chronic obstructive pulmonary disease (COPD).
    Panina P; Mariani M; D'Ambrosio D
    Curr Drug Targets; 2006 Jun; 7(6):669-74. PubMed ID: 16787169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging anti-inflammatory strategies for COPD.
    Cazzola M; Page CP; Calzetta L; Matera MG
    Eur Respir J; 2012 Sep; 40(3):724-41. PubMed ID: 22496331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD.
    Morjaria JB; Malerba M; Polosa R
    Drug Discov Today; 2010 May; 15(9-10):396-405. PubMed ID: 20223295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity.
    Freeman CM; Curtis JL; Chensue SW
    Am J Pathol; 2007 Sep; 171(3):767-76. PubMed ID: 17640964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic therapies for chronic obstructive pulmonary disease.
    Matera MG; Calzetta L; Cazzola M; Ora J; Rogliani P
    Expert Opin Biol Ther; 2023 Feb; 23(2):163-173. PubMed ID: 36527286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.
    Matera MG; Page C; Rogliani P; Calzetta L; Cazzola M
    Drugs; 2016 Sep; 76(13):1257-1270. PubMed ID: 27506851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-inflammatory drug development: Broad or specific chemokine receptor antagonists?
    Russo RC; Garcia CC; Teixeira MM
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):414-27. PubMed ID: 20597027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokines and their receptors in asthma and chronic obstructive pulmonary disease.
    Panina-Bordignon P; D'Ambrosio D
    Curr Opin Pulm Med; 2003 Mar; 9(2):104-10. PubMed ID: 12574689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokines in health and disease.
    Gangur V; Birmingham NP; Thanesvorakul S
    Vet Immunol Immunopathol; 2002 Jul; 86(3-4):127-36. PubMed ID: 12007879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for chronic obstructive pulmonary disease.
    Matera MG; Calzetta L; Segreti A; Cazzola M
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):61-82. PubMed ID: 22335427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease.
    Demedts IK; Bracke KR; Van Pottelberge G; Testelmans D; Verleden GM; Vermassen FE; Joos GF; Brusselle GG
    Am J Respir Crit Care Med; 2007 May; 175(10):998-1005. PubMed ID: 17332482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease.
    Kim V; Cornwell WD; Oros M; Durra H; Criner GJ; Rogers TJ
    BMC Pulm Med; 2015 Sep; 15():111. PubMed ID: 26424214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential new drugs for therapy of chronic obstructive pulmonary disease.
    de Boer WI
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1067-86. PubMed ID: 12831344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokines in COPD: From Implication to Therapeutic Use.
    Henrot P; Prevel R; Berger P; Dupin I
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31174392
    [No Abstract]   [Full Text] [Related]  

  • 20. Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells.
    Victoni T; Gicquel T; Bodin A; Daude M; Tenor H; Valença S; Devillier P; Porto LC; Lagente V; Boichot E
    Int Immunopharmacol; 2016 Jan; 30():1-8. PubMed ID: 26610096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.